

QQQESQQLQQCCN**QV**KQRDEC**QCEAIKYIAEDQIQQGQLH**GEESERVAQRAGEIVSS**CGVR**CMRQTR or
QERSLRG**CCDH**LKQM**QSQC**RCEGLRQAIEQQQS**QGQLQG**QDVFEAFRTAANLPSM**CGV**SPTECRF;
wherein specific amino acids of the consensus sequence are
indicated by boldface.

A / concua
Claim 4. (amended once) A glycoconjugate as claimed in Claim 1, wherein the polypeptide is stabilized by disulphur or dimethylene bridges, and can be oligomeric or dimeric.

Claim 5. (amended once) A glycoconjugate as claimed in Claim 1, wherein the glycoconjugate has pharmacological activity and can be used medically to treat disorders of an immunological system.

Claim 6. (amended once) A glycoconjugate as claimed in Claim 1, wherein the glycoconjugate can be used in pharmacy to prepare galenical forms.

A2
Please add the following new claim.

--Claim 7. A glycoconjugate as claimed in Claim 1, wherein the polypeptide has at least two disulphur or two dimethylene intercatenary bridges.--

REMARKS

Hereinafter, the claims that are pending prior to the entry of the amendments in this Preliminary Amendment are called

"originally filed claims." This Preliminary Amendment amends originally filed Claims 1-6 and adds new Claim 7. Upon amendment, the above-identified application will have one independent claims (amended Claim 1) and 7 total claims (amended Claims 1-6 and new Claim 7). Therefore, no fee is due for excess claims.

Support for amending originally filed Claims 1-6 can be found in, *inter alia*, originally filed Claims 1-6, respectively. Support for new Claim 7 can be found in, *inter alia*, originally filed Claim 4.

This Preliminary Amendment amends originally filed Claims 1-6 and adds new Claim 7. The amendments and addition described in the preceding sentence were done to claim the scope of the invention that the Applicants elect to claim and were not done to overcome the prior art, obviousness-type double-patenting rejections, or rejections under 35 U.S.C. § 112. The amendments and addition described in the first sentence of this paragraph shall not be considered necessary to overcome the prior art, obviousness-type double-patenting rejections, or rejections under 35 U.S.C. § 112.

The Applicant reserves the right to seek protection for any unclaimed subject matter either subsequently in the prosecution of the present case or in a divisional or continuation application.

The Commissioner is authorized to charge any additional fees which may be required or credit overpayment to Deposit Account No. 12-0415. In particular, if this Preliminary Amendment is not timely filed, then the Commissioner is authorized to treat

Preliminary Amendment
August 13, 2001
Page 5

this Preliminary Amendment as including a petition to extend the time period pursuant to 37 C.F.R § 1.136(a) requesting an extension of time of the number of months necessary to make this response timely filed; and the petition fee due in connection therewith may be charged to deposit account No. 12-0415.

Respectfully submitted,

John Palmer
Reg. No. 36,885
Attorney for Applicant
LADAS & PARRY
5670 Wilshire Boulevard #2100
Los Angeles, California 90036
(323) 934-2300

Enclosure: Appendix A (3 pages)

APPENDIX A

Re; New U.S. Patent Application
Application number not yet assigned
"Pharmacologically Active Polypeptide Glycoconjugates"
Our Ref.: 618999-1/JP/B-4275PCT

Claim 1. (amended once) [Glycoconjugates] A glycoconjugate formed by [the] non-covalent association of a [polysaccharides] polysaccharide with a [polypeptides] polypeptide, [characterized because the] wherein the polysaccharide [fraction] has a molecular weight between 50 and 250 [DKa] KDa, supporting phosphate functional groups in range 1 of these phosphate groups by between 5 and 25 residues of monosaccharide, with 40% mannose, and [the rest can be either] glucose and/or galactose, making up [the] a main skeleton integrated by 1-6 bonds with 1-2 branches not higher than 60%; wherein the polypeptide [fraction is characterized by comprising] comprises a consensus amino-acid sequence determined by $Z_{3-48}CZ_{9-13} C(Q,E,R,K) Z(Z_{\text{hydrophobic}}) (LIVM)Z_{15-39} CC(Z_{\text{hydrophilic}})$ $(Q,E,H) (L,V)Z_6 CZC Z_2(L,I)Z_{13-56}G Z_{15-26} CZ(V,I,L,M)Z_{1-8} CZ_{1-12}$, where the [symbols represent amino acids and the parenthesis] parentheses indicate [the] a preferential order, and [being] wherein Z_n [whatever] is selected from the group consisting of n-amino acids.

Claim 2. (amended once) [Glycoconjugates, according to the above claim,] A glycoconjugate as claimed in Claim 1, wherein [characterized by] the polypeptide [fraction being made up by] comprises one or two polypeptides, [as long as the] wherein a

APPENDIX A

mol/mol relation between the two polypeptides is between 1/3 and 3/1.

Claim 3. (amended once) [Glycocojugates, according to the first claim,] A glycoconjugate as claimed in Claim 1, wherein [characterized because] the polypeptide [fraction] is a dimer having a molecular weight of 12 ± 0.5 KDa, [with amino acid sequences selected between:] wherein the dimer has a minor subunit and a major subunit,

[Minor:] wherein the minor subunit is

[ESKG**E**REGSSSSQQ**C**RQEVQRKDLSS**C**ERYL**R**QSSSSRR]

ESKG**E**REGSSSSOO**C**ROEVORKDLSS**C**ERYL**R**QSSSSRR or

[PSQQ**G**CRGQ**I**QEQQNL**R**Q**O**EY**I**KQQVSGQGP**R**R]

PSOO**G**CRGO**I**O**E**Q**O**NL**R**CO**E**Y**I**K**O**Q**V**SG**O**GP**R**R; and wherein the major subunit is [Major:]

[QQQESQQLQQCC**N**OV**K**QVRDEC**C**Q**E**A**I**KYIAED**Q**IQQQLH**G**EE**S**ERVA**Q**RAGE**I**VSS**C**GV**R**CM**R**Q**T**R]

OOOESOO**L**O**O**CC**N**OV**K**QVRDEC**C**Q**E**A**I**KYIAED**Q**I**O**Q**G**OL**H****G**EE**S**ERVA**Q**RAGE**I**VSS**C**GV**R**CM**R**Q**T**R or

[QERSLRG**C**CD**H**L**K**QM**Q**S**Q****C**R**C**EG**L**RQ**A**I**E**QQ**Q**S**Q****G****Q****L****Q****G****D**V**F**EA**F**RT**A**AN**L****P****S****M****C****G****V****S****P****T****E****C****R****F**]

QERSLRG**C**CD**H**L**K**OMOSOC**R****C**EG**L**RQ**A**I**E**OO**O**SOGOLOGODV**F**EA**F**RT**A**AN**L****P****S****M****C****G****V****S****P****T****E****C****R****F**;

[and in which the] wherein specific amino acids of the consensus sequence are indicated by [underlining] boldface.

Claim 4. (amended once) [Glycocojugates, according to the first claim,] A glycoconjugate as claimed in Claim 1, wherein the [characterized because the structural] polypeptide [fraction] is stabilized by disulphur or dimethylene bridges, and can be oligomeric or [preferably] dimeric[, and in this case having at least two disulphur or dimethylene intercatenary bridges].

Claim 5. (amended once) [Glycocojugates, according to the first

APPENDIX A

claim,] A glycoconjugate as claimed in Claim 1, wherein the glycoconjugate [with] has pharmacological activity and [its application in medicine for the] can be used medically to treat [treatment of] disorders of [the] an immunological system.

Claim 6. (amended once) [Glycoconjugates according to the first claim and] A glycoconjugate as claimed in Claim 1, wherein the glycoconjugate [its application in pharmacy for its use in the preparation of usual] can be used in pharmacy to prepare galenical forms.